Genscript Biotech's revenue for the
six
months ended in Dec. 2023 was HK$3,500 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$6,566 Mil.
Genscript Biotech's Revenue per Share for the
six
months ended in Dec. 2023 was HK$1.66.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$3.11.
During the past 12 months, the average Revenue per Share Growth Rate of Genscript Biotech was 33.80% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 24.90% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 25.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 10 years, Genscript Biotech's highest 3-Year average Revenue per Share Growth Rate was 32.20% per year. The lowest was 21.50% per year. And the median was 26.40% per year.
Genscript Biotech Revenue Historical Data
The historical data trend for Genscript Biotech's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Genscript Biotech's Revenue
For the Biotechnology subindustry, Genscript Biotech's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genscript Biotech's Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genscript Biotech's Revenue distribution charts can be found below:
* The bar in red indicates where Genscript Biotech's Revenue falls into.
Genscript Biotech Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$6,566 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Genscript Biotech Revenue Related Terms
Thank you for viewing the detailed overview of Genscript Biotech's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Genscript Biotech (HKSE:01548) Business Description
GenScript Biotech is a China-based provider of life science research services and products. Founded in 2002, it is best known for its gene synthesis capabilities, a widely used service by academics, biotech companies, and pharmaceutical companies around the world. Its business lines include life science research services and products, biologics development services under its ProBio brand, and industrial enzymes under its Bestzyme brand. Finally, it owns 57.1% of Nasdaq-listed Legend Biotech, whose key pipeline asset is a BCMA-targeting CAR-T treatment for multiple myeloma. We estimate that more than two thirds of GenScript's valuation is from its ownership stake in Legend.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:01548 has been successfully added to your 